Creating a registry to analyze the microbiome in patients with urologic cancers
Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome
Yonsei University · NCT04625556
This study is trying to create a database to see how the bacteria in our bodies might affect the diagnosis and treatment of urologic cancers like prostate and bladder cancer in Korean patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Yonsei University (other) |
| Locations | 1 site (Seoul) |
| Trial ID | NCT04625556 on ClinicalTrials.gov |
What this trial studies
This study aims to develop a comprehensive registry focused on the microbiome's role in urological malignancies, including prostate, renal cell, bladder, and ureter cancers, within the Korean population. By analyzing microbiome samples from tissue, plasma, stool, and urine, the study seeks to enhance diagnosis, monitor disease progression, and evaluate therapeutic responses. The research will also build a large database to better understand the microbiome's impact on these cancers, addressing a significant gap in current knowledge.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with urological malignancies who have undergone surgery at Severance Hospital between October 2020 and October 2030.
Not a fit: Patients who do not agree to participate in the study or those who are considered vulnerable and unable to provide informed consent may not benefit.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and monitoring tools for patients with urological malignancies.
How similar studies have performed: While there have been limited studies on the microbiome's role in urological malignancies, this approach is relatively novel and underexplored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed as urological malignancies (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer) * Patients who have undergone surgeries due to urological malignancies in Severance Hospital, Sinchon from 2020.10 and 2030.10 * Those who agree to give permission to use their human source information * Those who agree with this study Exclusion Criteria: * Those who do not agree with this study * Vulnerable participants who are likely to be vulnerable to coercion or undue influence or lack decision-making
Where this trial is running
Seoul
- Yonsei Severance Hospital — Seoul, South Korea (RECRUITING)
Study contacts
- Principal investigator: Won Sik Ham — Severance Hospital
- Study coordinator: Won Sik Ham
- Email: uroham@yuhs.ac
- Phone: 82-02-2228-2310
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Urological Malignancies, Prostate Cancer, Renal Cell Cancer, Bladder Cancer, Ureter Cancer